The FDA is currently reviewing applications from Alkermes regarding the seeking of designation for the drug alixorexton for investigational use and narcolepsy.
1 report, 1 independent
Updated Jun 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is currently reviewing applications from Alkermes regarding the seeking of designation for the drug alixorexton for investigational use and narcolepsy.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- The FDA recommended advancement for a new drug application submitted by a company.
- The FDA is currently reviewing new drug applications for market entry.
- The FDA placed a clinical hold on the IND application for the company Aardvark.
- Alkermes and Eli Lilly are competing for market share in the narcolepsy drug space, utilizing research from Stanford University.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.